Taken together these findings provide strong rationale for anti-invasive therapies targeting CTGF, as this molecule was found to be significantly over-expressed in invasive glioma cells where knock-down studies confirmed biological activity. The gene discussed is CCN2; the disease is central nervous system cancer.